



24 September 2024

## **Medicine Supply Alert Notice**

### **Lanreotide 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml solution for injection pre-filled syringes**

**Priority: Level 2\***

**Valid until: end of November 2024**

#### **Issue**

1. Advanz Pharma's lanreotide 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml solution for injection pre-filled syringes are unavailable until at least end of November 2024.
2. New patient referrals to homecare providers for Advanz Pharma's lanreotide 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml solution for injection pre-filled syringes will not be accepted.
3. Ipsen's lanreotide (Somatuline Autogel®) 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml solution for injection pre-filled syringes remain available and can support increased demand.

#### **Advice and Actions**

4. NHS Board pharmacy procurement teams, working with the appropriate clinical specialists and their local pharmacy Homecare lead should:
  - not initiate new patients on any strength of Advanz Pharma's lanreotide solution for injection pre-filled syringes until the shortage resolves.
  - prescribe Somatuline Autogel® (lanreotide) solution for injection pre-filled syringes for new patient initiations under Ipsen's funded homecare service; and
  - be aware that patients established on Advanz Pharma's sponsored homecare scheme for all strengths of lanreotide solution for injection pre-filled syringes will receive the equivalent strength of Somatuline Autogel® pre-filled syringes as a substitution during this period to ensure continuity of treatment (see Additional Information section below).
5. Homecare providers should:
  - ensure that patients receiving substitution with Somatuline Autogel® pre-filled syringes are informed directly of the switch and offered nursing support; and
  - work with the prescriber and the Board homecare-lead to ensure nurse led training is provided or, if available, administration support is offered where requested.

#### **Additional Information**

##### **Clinical Information**

\*<https://www.nss.nhs.scot/media/1842/medicine-supply-alert-notice-definitions-of-classifications-21-october-2019.pdf>

6. Sciensus / Bionical Health and Alcura currently provide generic lanreotide 60mg/0.5ml, 90mg/0.5ml and 120mg/0.5ml solution for injection pre-filled syringes via Advanz Pharma's manufacturer-sponsored homecare scheme.
7. National Procurement at NSS will liaise with Alcura to establish a management plan for any affected patients and subsequently inform Homecare leads.
8. Sciensus has implemented the following management plan to ensure continuity of supplies to patients during this period:
  - The annotation of all affected prescriptions to allow for the substitution with lanreotide (Somatuline Autogel®) 90mg/0.5ml for injection pre-filled syringes.
  - Bionical Health provide nursing for this service. National Procurement will liaise with Bionical to establish a management plan for any affected patients and subsequently inform Homecare leads.
9. All delivery fees and nurse support fees irrespective of the brand of lanreotide dispensed would be funded by Advanz Pharma. Where there is substitution of Ipsen Somatuline Autogel® pre-filled syringes, the Ipsen price will be charged to the NHS.

#### Links to further information

- [BNF Lanreotide](#)
- [SmPC Lanreotide](#)

#### **Specialist Pharmacy Service (SPS) website**

10. The UK Department of Health and Social Care (DHSC) in conjunction with SPS have launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. To access the online Medicines Supply Tool you need to register with the [SPS website](#). Registration for access to the website is available to UK healthcare professionals and organisations providing NHS healthcare. The tool is located under the Tools tab and then click on the Medicines Supply option.
11. We encourage prescribers, pharmacy professionals, and pharmacy procurement leads in Scotland to register with the SPS website and use its Medicine Supply Tool to stay up to date concerning medicines supply disruptions. Please be aware that while medicines supply issues will appear on the SPS website, some of the recommended actions may not always be appropriate / relevant within the Scottish context.

#### **Enquiries**

12. Enquiries from Health Boards or healthcare professionals should be directed in the first instance to [PharmacyTeam@gov.scot](mailto:PharmacyTeam@gov.scot) (primary care) or [NSS.NHSSMedicineShortages@nhs.scot](mailto:NSS.NHSSMedicineShortages@nhs.scot) (secondary care).